Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple Sclerosis (MS)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    505 result(s) found for: Multiple Sclerosis (MS). Displaying page 10 of 26.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    EudraCT Number: 2009-010788-18 Sponsor Protocol Number: CAMMS03409 Start Date*: 2009-07-01
    Sponsor Name:Genzyme Corporation
    Full Title: An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) SE (Completed) AT (Completed) PL (Completed) CZ (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012500-11 Sponsor Protocol Number: 205MS301 Start Date*: 2010-04-12
    Sponsor Name:Biogen Idec Ltd
    Full Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) DE (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) ES (Completed) GB (Completed) GR (Completed) IT (Completed) DK (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2008-008719-25 Sponsor Protocol Number: CBAF312A2201 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005160-41 Sponsor Protocol Number: ALK8700-A301 Start Date*: 2016-07-27
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) PL (Completed) ES (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020328-23 Sponsor Protocol Number: EMR200136-532 Start Date*: 2010-10-21
    Sponsor Name:Merck Serono
    Full Title: A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sc...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) DE (Completed) DK (Completed) BE (Prematurely Ended) IT (Completed) LT (Completed) EE (Completed) LV (Completed) AT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001081-99 Sponsor Protocol Number: MS/MOGMOD/CT/FIH/01 Start Date*: 2014-12-16
    Sponsor Name:ImCyse S.A
    Full Title: A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by ...
    Medical condition: Multiple sclerosis is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system. MS is characterized initially by episodes of reversible neurologic deficit...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015007-97 Sponsor Protocol Number: DEFENCE Start Date*: 2010-02-16
    Sponsor Name:DR. ENRICO MONTANARI
    Full Title: Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography (OCT) to Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCutaneous IFN bEta 1a
    Medical condition: Patients with RR-MS diagnosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014724-32 Sponsor Protocol Number: SABA Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Eppendorf
    Full Title: SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEK...
    Medical condition: Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002566-13 Sponsor Protocol Number: NEXT-MS Start Date*: 2019-12-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012716-40 Sponsor Protocol Number: CO-200-201 Start Date*: 2009-12-31
    Sponsor Name:Peptimmune Inc.
    Full Title: The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel,...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Completed) DE (Completed) FR (Ongoing) PL (Prematurely Ended) SK (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005125-11 Sponsor Protocol Number: RCT-EPO-001 Start Date*: 2008-12-19
    Sponsor Name:Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
    Medical condition: Primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-006262-40 Sponsor Protocol Number: 215MS201 Start Date*: 2013-06-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of ...
    Medical condition: Relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) NL (Completed) HU (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008065-35 Sponsor Protocol Number: TYNERGY Start Date*: 2009-03-13
    Sponsor Name:BiogenIdec A/S
    Full Title: A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the c...
    Medical condition: Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10016256 Fatigue LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002633-20 Sponsor Protocol Number: A4M105038 Start Date*: 2006-11-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004702-17 Sponsor Protocol Number: COMB157G2102 Start Date*: 2018-09-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) EE (Completed) LV (Completed) LT (Completed) ES (Completed) PL (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004846-31 Sponsor Protocol Number: 386022010017 Start Date*: 2017-12-14
    Sponsor Name:University medical centre Maribor
    Full Title: Impact of vitamin D supplementation in patients with multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001940-38 Sponsor Protocol Number: RMFD5-10 Start Date*: 2008-04-22
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function.
    Medical condition: patients affected by multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007759-15 Sponsor Protocol Number: CO-200-102 Start Date*: 2008-11-10
    Sponsor Name:PEPTIMMUNE Inc
    Full Title: The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized,...
    Medical condition: Patients with current diagnosis of SP-MS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002561-38 Sponsor Protocol Number: SVUHneuro002 Start Date*: 2012-03-30
    Sponsor Name:St. Vincent's University Hospital
    Full Title: A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003775-11 Sponsor Protocol Number: Start Date*: 2012-01-12
    Sponsor Name:
    Full Title: Fluoxetine therapy for multiple sclerosis
    Medical condition: progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    16.0 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    16.0 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:24:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA